GlassScriptPhysician profile
Deon Tolliver
NPI 1780096933
$2,106.66
in general payments reported to CMS, 2019-2025
34 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.35 · 2021: $227 · 2022: $79.68 · 2023: $195 · 2024: $1,138 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.37 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $251.15 | 2023-2025 | Rexulti, Vyepti |
| Lilly USA, LLC | $215.21 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $148.88 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $140.01 | 2024 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $116.47 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $111.86 | 2021-2024 | Fanapt, Hetlioz |
| Amgen INC. | $107.02 | 2024 | Otezla, Repatha, Prolia |
| Neurelis, INC. | $105.77 | 2023 | Valtoco |
| Baxter Healthcare | $69.02 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Axsome Therapeutics, INC. | $68.82 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $56.17 | 2021-2024 | Bexsero, Pediarix, Rotarix |
| Supernus Pharmaceuticals, INC. | $52.28 | 2024-2025 | Qelbree |
| Corium, LLC | $52.03 | 2024-2025 | Azstarys |
| Astellas Pharma US INC | $51.41 | 2025 | Veozah |
| Boston Scientific Corporation | $50.28 | 2024-2025 | Bodyguardian |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.84 | 2024 | |
| Novo Nordisk INC | $47.49 | 2024-2025 | Rybelsus, Ozempic |
| Ultragenyx Pharmaceutical INC. | $43.46 | 2024 | Crysvita |
| Ucb, INC. | $40.95 | 2024 | Nayzilam |
| Collegium Pharmaceutical, INC. | $33.26 | 2024 | Belbuca |
| Harmony Biosciences LLC | $29.83 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.63 | 2024-2025 | Jardiance |
| Hologic Sales and Service, LLC | $22.92 | 2025 | Aptima |
| Dexcom, INC. | $22.16 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $22.16 | 2024 | Voquezna |
| Alkermes, INC. | $21.95 | 2022 | |
| Verona Pharma, INC. | $20.91 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $20.82 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $20.75 | 2021 | |
| Seqirus USA INC | $19.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.24 | 2025 | |
| Philips North America LLC | $17.58 | 2024 | (Ck4) Mcot |
| Inspire Medical Systems, INC. | $16.46 | 2024 | Inspire |
| Tonix Medicines, INC. | $14.04 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deon Tolliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.